Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI
Journal of Magnetic Resonance Imaging · 2023
DOI: 10.1002/jmri.28671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2023. Verfasst von Hongbo Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Brain Neoplasms, Deep Learning, Glioblastoma, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Studies have shown that magnetic resonance imaging (MRI)‐based deep learning radiomics (DLR) has the potential to assess glioma grade; however, its role in predicting telomerase reverse transcriptase (TERT) promoter mutation status in patients with glioblastoma (GBM) remains unclear.
Purpose
To evaluate the value of deep learning (DL) in multiparametric MRI‐based radiomics in identifying TERT promoter mutations in patients with GBM preoperatively. Study Type Retrospective. Population A total of 274 patients with isocitrate dehydrogenase‐wildtype GBM were included in the study. The training and external validation cohorts included 156 (54.3 ± 12.7 years; 96 males) and 118 (54 .2 ± 13.4 years; 73 males) patients, respectively. Field Strength/Sequence Axial contrast‐enhanced T1‐weighted spin‐echo inversion recovery sequence (T1CE), T1‐weighted spin‐echo inversion recovery sequence (T1WI), and T2‐weighted spin‐echo inversion recovery sequence (T2WI) on 1.5‐T and 3.0‐T scanners were used in this study. Assessment Overall tumor area regions (the tumor core and edema) were segmented, and the radiomics and DL features were extracted from preprocessed multiparameter preoperative brain MRI images—T1WI, T1CE, and T2WI. A model based on the DLR signature, clinical signature, and clinical DLR (CDLR) nomogram was developed and validated to identify TERT promoter mutation status. Statistical Tests The Mann–Whitney U test, Pearson test, least absolute shrinkage and selection operator, and logistic regression analysis were applied for feature selection and construction of radiomics and DL signatures. Results were considered statistically significant at P ‐value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China.
- Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
ORCID-Profile: Hongbo Zhang, Biao Huang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Zhang, H., Zhang, Y., Zhou, B., Wu, L., Lei, Y., & Huang, B. (2023). Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.28671
Vancouver
Zhang H, Zhang H, Zhang Y, Zhou B, Wu L, Lei Y, et al. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI. Journal of Magnetic Resonance Imaging. 2023. doi:10.1002/jmri.28671
BibTeX
@article{Zhang2023,
author = {Zhang, Hongbo and Zhang, Hanwen and Zhang, Yuze and Zhou, Beibei and Wu, Lei and Lei, Yi and Huang, Biao},
title = {Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI},
journal = {Journal of Magnetic Resonance Imaging},
year = {2023},
doi = {10.1002/jmri.28671}
}
EUVIMED